MIGENIX to Initiate MX-3253 HCV Viral Kinetics Study in Treatment Naive Patients; CEO Message No. 17 Released
VANCOUVER, BC and SAN DIEGO, CA, Jan. 23 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, released the Company's 17th CEO Message
today.
The CEO Message provides an overview of the MX-3253 and CPI-226 clinical programs for 2006 and the first half of 2007, including the Company's plan to initiate a combination therapy viral kinetics clinical trial of celgosivir (MX-3253) in Hepatitis C virus (HCV) patients.
Celgosivir is an orally administered, first- in-class alpha glucosidase 1 inhibitor, in development for the treatment of chronic HCV infections.
The viral kinetics study is intended to demonstrate improved viral load kinetics (antiviral activity) in treatment-naive HCV patients when celgosivir is used in combination with interferon over a treatment period of up to 28 days.
The study is expected to start early in the second quarter of calendar 2006, with results in the second half of calendar 2006.
Jim DeMesa, M.D., President and CEO of MIGENIX stated, "This viral kinetics study provides us another significant clinical result in HCV patients in 2006.
In mid-year 2006 we will have results from our MX-3253 Phase IIb study in HCV 'non-responder' patients initiated in November 2005 with support from Schering-Plough.
These results, along with the CPI-226 Phase III clinical
results expected in the first half of 2007 provide us several near-term value driving opportunities".
To obtain a copy of the complete CEO Message, please visit the MIGENIX web site at migenix.com or contact Investor Relations at 1-800-665-1968, Extension 241.
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase
II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I) and the treatment of acne (Phase II).
MIGENIX is headquartered in Vancouver, British Columbia, Canada with US
operations in San Diego, California. Additional information can be found at
migenix.com.
prnewswire.com |
